CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Shares Sold by Wellington Shields & Co. LLC

Wellington Shields & Co. LLC decreased its holdings in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 30.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 30,091 shares of the biotechnology company’s stock after selling 13,000 shares during the period. Wellington Shields & Co. LLC’s holdings in CASI Pharmaceuticals were worth $85,000 as of its most recent filing with the Securities and Exchange Commission.

Analyst Ratings Changes

Separately, StockNews.com started coverage on CASI Pharmaceuticals in a research report on Tuesday, March 11th. They set a “hold” rating on the stock.

CASI Pharmaceuticals Price Performance

Shares of NASDAQ:CASI opened at $2.20 on Friday. The business’s 50 day simple moving average is $2.49 and its 200-day simple moving average is $4.19. The firm has a market capitalization of $34.15 million, a price-to-earnings ratio of -0.99 and a beta of 0.41. The company has a debt-to-equity ratio of 1.38, a current ratio of 3.20 and a quick ratio of 2.32. CASI Pharmaceuticals, Inc. has a 12 month low of $2.04 and a 12 month high of $7.67.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.